<?xml version="1.0" encoding="UTF-8"?>
<p>Finally, before the COVID-19 pandemic, important strides had been made in compensating victims of opioid manufacturers' malfeasance. For example, in August 2019, the state of Oklahoma won a $572 million lawsuit against Johnson &amp; Johnson, with the judge ruling that the company overstated the benefits and understated the risks of opioid products, thus violating the state's public nuisance laws (
 <xref rid="r8-1210" ref-type="bibr">8</xref>). These monies will go to victims' families and help bolster Oklahoma's addiction treatment resources. Delays in court hearings could backlog 2000 similar lawsuits and significantly delay remuneration, which is especially damaging given the looming economic crisis in the United States. To provide much-needed funding in the midst of these 2 crises, we urge acceleration of cases nearing resolution, a prominent one being Purdue Pharma's bankruptcy case, resolution of which could mean more than $10 billion to families and addiction treatment agencies (
 <xref rid="r9-1210" ref-type="bibr">9</xref>).
</p>
